Immuneering assumed with an Outperform at Oppenheimer

Oppenheimer analyst Jay Olson assumed coverage of Immuneering with an Outperform rating and $25 price target. There was no change to the firm’s estimates or price target, and Oppenheimer’s rating remains intact.